Funding

Funding Application Information

Type B Deadline: There will not be a call for Spring 2025 Type B applications. Check back often for other funding opportunities. Type A applications are still being accepted on a rolling basis.

The NIDDK Hematology Centers Program is providing a novel support mechanism for researchers to pursue new directions in non-malignant hematology. Applicants do not need to be U.S. citizens or Green card holders but must be from any registered, domestic (U.S.), eligible organization. However, those from institutions not currently part of the NIDDK Hematology Centers Program will be prioritized. Applications from investigators coming from other fields, bringing new perspectives or tools to address questions in nonmalignant hematology are also encouraged to apply.

P&F Type A: $5,000 – $12,000 worth of core credits to provide equal access to services and expertise offered by any core. Rolling deadlines, abbreviated application forms, and streamlined review by Core Directors all contribute to a rapid and equitable distribution of core credits. Type A support is ideally suited for trainees who want to master a new expertise or acquire a new skill to enhance their competitiveness. Applications for Type A projects will be accepted on a rolling basis and reviewed on an as needed basis.

Instructions Specific to P&F Type A: New applications should be uploaded as a single PDF file (11-point Arial font size and 0.5” margins) that must include:

Page 1. Title, PI; Abstract (made public if awarded).
Page 2. Description, Significance, Figures and Literature Cited,
Page 3. Core use, Budget, and Justification, (signed by lab PI, if trainee/junior investigator), 1 page

NIH-style Biosketch for applicant only.

Type A projects do not require Institutional sign off by the applicant’s grant and contract office, unless required by the applicant institution’s policies.

Applicants must obtain signed approval for costs and feasibility from the directors of the cores they wish to access.

Project periods are limited to 12 months, and a progress report must be submitted within 120 days of the budget end date.

P&F Type B: $75,000 total award (grant) including F&A. Use of CCEH Core resources is not required but encouraged.

The primary goal of Type B P&F grants is to support innovative pilot research projects in non-malignant hematology, including the generation of preliminary data for larger research grants. Pilots should involve new scientific directions or the development or application of a novel technology. It is not expected that any preliminary data be provided, but the scientific premise should be supported by literature. Applicants may apply for travel monies (up to $2,500) to train for 3-5 days at a CCEH core that will be utilized in the Type B proposal. These funds are a line item in the $75,000 maximum budget and may only be used to support flight, room and board costs for the investigator. Permission for travel must be approved by the Director of the CCEH core and the U24 Enrichment Chair (shannon.elf@hci.utah.edu).

Type B grants will be reviewed by a panel of approximately 10 reviewers, each reading all applications. Reviewers will provide scores for key review criteria (significance, innovation, approach, feasibility, as well as for new direction/technology and fostering a new collaboration) then rank all applications. Reviewers will briefly describe what drove their ranking. Applications will undergo a second level of review involving the NIDDK and the HCCC. Unsuccessful applicants will be encouraged to discuss the critiques with the scientific contact below.

This program is intended to support pilots that are not appropriate for other grant mechanisms. While applicants of any career stage are eligible, applicants will be required to describe why the project is not appropriate for other grant mechanisms (NIDDK fellowship, career development award, or research project (R) grants). Moreover, trainees, fellows and graduate students will be required to describe how the pilot will support a subsequent grant application and lead to future independence (e.g., how the research direction will differentiate them from their mentor).

Proposed research should address the NIDDK/Hematology mission to be considered for review. The following link describes the NIDDK hematology mission. NIDDK Hematology Program Directors are available to discuss the mission as well as relevant funding opportunities:

https://www.niddk.nih.gov/research-funding/research-programs#hematologic-disease

Applications that scientifically overlap with a NIH application that is currently under review will not be reviewed. Questions about these policies should be directed to the scientific contact below.

Instructions Specific to Type B: New applications should be uploaded as a single PDF file (11-point Arial font size and 0.5” margins). Resubmissions are not permitted; revised applications must be submitted as New. Only complete applications received by the due date will be reviewed.

Use the PHS 398 form including face, abstract (to be made public upon award), detailed budget, biographical and other support pages, and research plan.

Research plan is limited to 4 pages and should include:

Snapshot (1 page)
Under separate headers answer the following questions:
Elevator Pitch: How is the proposed pilot research a new direction in non-malignant hematology? Reference any current or pending Other Support from the PI, collaborators, or mentors, and describe how the pilot is not incremental.
Appropriateness of mechanism: How is the proposed research a fit for the Type B P&F grant, AND not a fit for another NIDDK grant mechanism? Investigators eligible for NIDDK fellowships or career development awards are strongly encouraged to apply for those mechanisms. Investigators with substantial preliminary data are strongly encouraged to apply for a research project grant (e.g., R01).
Pathway to independence (for applicants without independent faculty positions): How will the proposed pilot research help differentiate the trainee/fellow from their mentor(s)?
Specific Aims, Background and Significance (address all review criteria detailed above, 1 page)
Research Design and Methods (2 pages)

Pages not counted, but to be included are:

Literature Cited
Vertebrate Animals and/or Protection of Human Subjects Approval (if applicable)
Sharing Plan
Budget – Note: Budgets are limited to $75,000 total costs (inclusive of all F&A costs, PHS 398 FP4 and FP5) and will be administered as a subaward. The intent of these awards is to be a steppingstone for junior investigators to generate the data that will allow them to apply for other training or research awards. Please see the guidelines for F&A (8% for research training awards, https://grants.nih.gov/grants/policy/nihgps/html5/section_7/7.4_reimbursement_of_facilities_and_administrative_costs.htm). Applicants are encouraged to work with their Office of Sponsored Projects to allow training award rates to be used in this award.

For any application proposing to use CCEH Cores, applicants must obtain signed approval for costs and feasibility from the directors of the cores they wish to access and include on Budget justification page (CCEH Cores can be found here).

Applications from junior trainees/researchers must include a signed letter of support from their sponsor/PI.

Project periods are limited to 12 months, and a progress report must be submitted within 120 days of the budget end date.

Please upload a single PDF of your application using the “Submit Application Here”, at the end of the Funding Opportunities section (below).

For questions about application submission and receipt, please contact Derek Stirewalt: dstirewa@fredhutch.org.

For scientific questions, please contact Shilpa Hattangadi: hattangadism@nih.gov.

Additional Requirements

If an award is made, the submitted Abstract will be made public on the cceh.io website, along with the Project Title, PI Name(s), Institution, and award type.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number U24DK126127. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Awardees are also encouraged to refer to the “NIDDK Cooperative Centers of Excellence in Hematology Pilot &Feasibility Award” on their Biosketch and Other Support documents.

Awardees are expected to submit a final progress report within 120 days of the budget end date. The U24-funded HCCC may include this report, in part or in full, with its Annual Research Performance Progress Report (RPPR) to the NIH.

The HCCC may contact the PI of awards to review long-term outcomes. Awardees will be invited to present results at the annual NIDDK Hematology Centers Program Steering Committee meeting.

If not used in publications or grant submissions, data should be represented in Synapse or another relevant data repository as negative results.

Application Process for Type A or Type B P&F Proposals

1. Check guidelines for eligibility
a. Priority will be given to Junior Investigators and Postdocs.
b. Established Investigators starting a new line of Research in nonmalignant hematology – cannot be focused on currently funded project.

2. Determine the type of grant you wish to apply for.
a. Type A – Core Usage Funds Only (C-UFO) up to $12,000 (no F&A, funds made available only at Core proposed).
b. Type B – New Pilot Proposal (HCCC-P&F) up to $75,000 including recommended F&A (Use PHS 398 forms as detailed).

3. Contact the core director(s) of the core you will be using to initiate guidance on feasibility and costs associated with core use.

4. Write and submit proposals as a single PDF using the detailed guidelines on length and inclusions on the FUNDING link cceh.io/funding (“red” Submit box) prior to final due date and time.

No applications will be accepted after 5pm MST on the due date.

Submit Application Here

The CCEH program supports pilot and feasibility program grants funding small projects aimed at generating preliminary data for inclusion in larger grant applications. The grants will be awarded competitively and are designed to support collaborative research projects that utilize core resources at one of the five CCEH centers.

Please refer to the guidelines for writing and formatting applications (above) before submitting. Applications can be uploaded using the form to the right. You will receive rapid acknowledgement of receipt of your application via email. If you do not receive acknowledgement, please confirm the correct email address is provided and resubmit prior to the deadline. Please reach out to Lori Blake prior to the deadline to confirm that your application has been received lblake@fredhutch.org for assistance prior to the deadline.

No applications will be accepted after the due date.

Publications Associated with P&F Funding

Is the erythropoietin-erythroferrone-hepcidin axis intact in human neonates?

Maternal prolactin or estrogen signaling in hepatocytes does not regulate iron homeostasis during pregnancy

Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies.

Current or Past Recipients

Xia Xiao, PhD

Xia completed her PhD degree in Nutritional Sciences at the Pennsylvania State University, University Park. Under the mentorship of Dr. Matam Vijay-Kumar, she studied the roles of the innate immune proteins lipocalin 2 and myeloperoxidase in iron toxicity-induced liver damage, and the interplay among innate immune proteins, bacterial siderophores, and iron on innate immune function and gut health. For her postdoctoral training, Xia joined Dr. Jodie Babitt Lab at Massachusetts General Hospital/Harvard Medical School studying BMP-SMAD signaling, hepcidin regulation and iron homeostasis. This U24 CCEH Type B P&F award from NIDDK will provide her resources and experience to study the role of the hemochromatosis gene HFE in hepcidin regulation and iron homeostasis.

Emily Collins, PhD

Emily Collins, PhD, is a Postdoctoral Researcher in the lab of Anthony Rongvaux at Fred Hutchinson Cancer Center. With the support of CCEH, her research is focused on developing a CRISPR-based functional in vivo Screen of Human Hematopoiesis (C-FiSHH). This project proposes to combine CRISPR screen technology with the Rongvaux lab’s expertise in humanized mouse models to create a new tool to probe the essential mechanisms that maintain hematopoiesis and give rise to varied immune cell lineages. C-FiSHH will provide a necessary complement to the high-dimensional mapping of human hematopoiesis transcriptomes, adding a functional perspective to descriptive studies. The first goal is to deliver a protein-barcoded gRNA/CAS9 complex to human donor hematopoietic stem cells that will then successfully engraft in the MISTRG mouse model. We will then demonstrate the feasability of a multi-gene screen approach by delivering a CRISPR library of well-described genes involved in the development of the major hematopoietic lineages. Once developed, this approach intends to be highly versatile to accommodate any genes of interest and will help elucidate mechanisms underlying fundamental characteristics of hematopoiesis, such as the long-term maintenance of self-renewing HSCs, lineage commitment, or the role of cytokines.

Yagna Jarajapu, Type B P&F Recipient

Yagna is a vascular pharmacologist by training; received doctorate in vascular Physiology and Pharmacology from the Glasgow Caledonian University, Glasgow, Scotland. He had post-doctoral training in the field of ischemic vascular regeneration by adult stem/progenitor cells and the pharmacology of renin angiotensin system under the mentorship of Prof. Grant and Prof. Raizada at the University of Florida. As an independent investigator at the North Dakota State University he pursued research in ACE2 and Mas receptor pharmacology in the CD34+ stem/progenitor cells from diabetic adults. Collectively, his studies showed that activation of ACE2 or Mas receptor by pharmacological or molecular strategies is sufficient to enhance endothelialization or revascularization potential of the dysfunctional diabetic CD34+ cells in preclinical studies involving ischemic vascular injury. During the course of this research, his team identified that mitochondrial telomerase reverse transcriptase (mtTERT) is critical for restoring the reparative functions of diabetic CD34+ cells. Furthermore, the expression of dominant negative mutants of TERT, deletion splice variants, was higher in diabetic cells, which indeed impair the protective functions of mtTERT. The U24 CCEH type B P&F award will provide resources to study the pathological role of TERT-splice variants on the mitochondrial stress and bioenergetics, and hematopoietic functions in CD34+ cells.

Amy Medlock, PI University of Georgia Member Utah U54 CCEH

The CCEH Type B grant entitled “Erythroblastic Island Heme Synthesis under Normal and Inflammatory Conditions” in the Medlock laboratory is focused on understand the transcriptomics and proteomics at the single cell level of developing erythroid cells in erythroblastic islands under normal and disease states. The model we are using was developed in the Torok-Storb laboratory and allows the development of erythroblastic island from CD34+ cells. This systems allow us to probe the complex interaction of the central macrophage with the developing erythroid cells. Our first goal is to establish a time line for heme synthesis during erythropoiesis in this system that more closely resembles the bone marrow niche. Personnel from the Medlock laboratory traveled to the Fred Hutchinson Cancer Center to learn how to isolate CD34+ cells from adult bone marrow, grow, transform, and differentiate these cells. We also carried out flow analysis and single cell Western on the cells from these erythroblastic islands. Currently, we are continuing these experiments and starting single cell RNA-seq experiments. The second aim is to characterize the impact that the inflammatory response has on heme synthesis and differentiation of the erythroblasts within the erythroblastic island. These experiments will begin in the spring.

P&F recipient, James Ropa, PhD

James is currently a postdoctoral fellow at Indiana University School of Medicine where he has worked under the mentorship of first Dr. Hal Broxmeyer and now Dr. Mark Kaplan. He is in the process of transitioning to an independent position. James’s research is broadly focused on identifying the molecular machinery important for hematopoietic cell potency in various homeostatic/diseased/stressed states, with the overall goal of improving hematopoietic cell therapies. This CCEH supported study will identify gene programs that correlate with and/or drive hematopoietic stem and progenitor cell function by modeling the hematopoietic transcriptome against clinical readouts of potency and predicted potency. The objective of the project is to identify genes that are highly expressed in potent umbilical cord blood units and/or that drive better outcomes in hematopoietic transplantation. These data will have immediate translational implications for cord blood (and other donor sources) unit selection for use in cellular therapies, as well as for identifying molecular targets to improve cell function for other therapeutic utilities.

Radoslaw Omelianczyk, PhD

Radoslaw received his doctorate from the Nanyang Technological University in Singapore where he worked in the lab of Dr. Peter Preiser. He studied virulence genes of the human malaria parasite Plasmodium falciparum. He is receiving his postdoctoral training in the labs of Dr. Ellen Leffler and Dr. Paul Sigala (Utah CCEH) at the University of Utah. He is studying recently identified adaptations of Plasmodium falciparum that allow the parasite to thrive in otherwise resistant sickle disease patients. The Sickle allele provides near complete immunity to severe malaria, which caused allele frequencies to reach almost 20% in Sub-Saharan Africa. The spread of adapted parasites would therefore put large parts of the population at increased risk to get malaria. The U24 CCEH type B P&F grant is used to study the biological roles of these adaptations. Specifically, he hypothesizes that mutant parasites interfere with red blood cell metabolome and lipid composition.

Liang Zheng, PhD University of Kansas Medical Center

ANKRD26 (Ankyrin repeat domain-containing protein-26) is a highly conserved protein that is involved in platelet production. Mutations in the 5′ untranslated region (5’UTR) of ANKRD26 gene lead to ANKRD26 overexpression during megakaryocyte differentiation. resulting in impaired proplatelet formation. Point mutations and small size deletions in the 5’UTR of ANKRD26 have been identified in patients with inherited thrombocytopenia 2 (THC2), a life-long thrombocytopenia with a predispostion to developing hematological malignancies, However, little is known about the underlying mechanism of ANKRD26 mutation-associated thrombocytopenia. To explore the function of ANKRD26 and its role in magakaryopoiesis and thrombocytopenia, we established and characterized the first animal model of THC2. Our preliminary results demonstrated that zebrafish ankrd26 mutants with mutations in the 5’UTR of ankrd26 resulted in overexpression of Ankrd26 and reduction of thrombocyte count, similar to the clinical presentation of THC2 patients. Moreover, we found that the level of ANKRD26 was positively correlated with the level of PRMT1 in the megakaryoblastic leukemeia cells and in the platelets of immune thrombotic thrombocytopenic purpura patients. PRMT1 is an arginine methyl-transferase for RUNX1 (runt-related transcription factor 1), which is a negative regulator for ANKRD26 expression. We hypothesize that dysregulation of PRMT1-RUNX1-ANKRD26 pathway may affect both hereditary and acquired thrombocytopenia. Our study will further evaluate the role of this novel pathway in platelet development and production, providing a potential avenue for developing novel therapeutic strategies for patients with thrombocytopenia.

Type B P&F Recipient Audrey Belot

Audrey completed her BS degree in Physiology and Cell Biology at the University of Bretagne Occidental, Brest, France. She then joined the lab of Dr Delphine Meynard at the Paul Sabatier University, Toulouse, France to pursue her MS and PhD degrees. Her PhD work focused on understanding the role of iron in liver pathophysiology, specifically in NAFLD and NASH. In parallel, she also tested a new therapeutic strategy, LJ000328 an ALK2/3 kinase inhibitor, to treat Iron Deficiency Iron Refractory Anemia. In August 2021, Audrey started her post-doctoral research with Dr Iqbal Hamza at the University of Maryland, Center for Blood Oxygen Transport and Hemostasis where she studies heme transport and trafficking during erythropoiesis. The funding from the Type B P&F from the NIDDK CCEH will provide her with resources and experiences to support her long-term career goals of becoming an independent researcher.

Current P&F Projects

Title	PI, Key Personnel, Mentor, etc.	Investigator Institutions	Center/Core(s) to Be Used	At Center/Core Institutions	Award Type	Award Year
Training a machine learning model to identify long-term engrafting HSCs	Helong Gary Zhao, PhD	Fred Hutchinson Cancer Center	Hematopoietic Cell Procurement and Processing Core	Fred Hutch	Type A	2024
Investigating Long-Term Genome Editing Safety in Hematopoietic Stem Cells	YoonA Kang, PhD	Washington University School of Medicine	Fred Hutchinson CCEH Cell Procurement and Processing Core		Type B	2024
Uncovering RNA isoform diversity and functionality in hematopoietic cell-fate determination	Stanley Lee, PhD	Fred Hutchinson Cancer Center	None	Fred Hutchinson CCEH	Type B	2024
Dissecting microenvironmental metabolic contributions to erythropoiesis	Marlies P Rossmann, PhD	University of Rochester	Cincinnati CCEH Single Cell Characterization and Procurement Core		Type B	2024
Investigating Long-Term Genome Editing Safety in Hematopoietic Stem Cells	Phillip A Doerfler, PhD	Versiti Blood Research Institute	Cell Procurement and Processing	Fred Hutchinson CCEH	Type A	2024
Minimal manipulation of HPSCs and novel viral vectors for faster, efficient transduction of hematopoietic stem and progenitor cells	Rachel Bakyayita Kyeyune, MBChB, PhD	Fred Hutchinson Cancer Center	Cell Procurement and Processing Fred Hutchinson CCEH	Fred Hutchinson CCEH	Type A	2024
Changes in the bone marrow microenvironment in cystic fibrosis	Emanuela Bruscia, PhD	Yale Medical School	Flow and Tissue Cytometry Core Indiana Univ CCEH	Yale CCEH	Type A	2024
Critical Role of a SNP in the SENP1 gene regulation and excessive erythrocytosis at high altitude	Dr. Priti Azad	Univ. California San Diego	Yale Prep and Analysis Core	None	Type A	2024
The function of neutrophilic granule protein in hematopoietic development	Kostandin V. Pajcini PhD. Associate Professor, University of Illinois at Chicago. kvp@uic.edu	Indiana University School of Medicine	Cincinnati Transgenic Animal and Genome Editing Core	None	Type A	2024
Gene Expression Profiling to Predict Hematopoietic Cell Potency in Transplantation	James Ropa, PhD	Indiana University School of Medicine	IU-CCEH Flow Cytometry and Cincinnati Children’s CCEH DNA Sequencing Cores	Indiana CCEH	Type B	2024
Investigation of selective autophagy receptor optineurin in erythropoiesis.	Massiel Chavez Stolla, PhD	University of Washington School of Medicine	None	Fred Hutchinson CCEH	Type B	2024
Improving hematopoietic stem cell quantification in a sickle cell disease contextn	Kim Vanuytsel, PhD	Boston Medical Center	Yale CCEH Primary Cells CD34+ Core	None	Type B	2024
Metabolic determinants of MEP fate specification	Rubia Mancuso, PhD	Yale Medical School	Yale CCEH	Utah Metabolomics Core	Type A	2024
Metabolic Changes in Erythroblasts from Iron-Regulatory Protein 2 Phosphorylation Mutant Mice	Elizabeth A. Leibold, PhD	University of Utah, Department Internal Medicine, Hematology Division and Molecular Medicine Program	Metabolomics	Utah CCEH	Type A	2024
Using a Novel CODEX Antibody Panel for Spatial Cellular Proteomics of the Bone Hematopoietic and Vascular Niches under Systemic Thrombopoietin Treatment	Patrick Mulcrone, PhD	Indiana University School of Medicine	Flow and Tissue Cytometry Core	Indiana CCEH	Type A	2023
Interactions between heme export and choline import via FLVCR1	Janis L Abkowitz, MD	University of Washington	Metabolomics	University of Utah	Type A	2023
Investigating aging-related changes in the bone marrow matrix and hematopoietic stem cell niche using multiplexed spatial-resolution imaging	Milos Marinkovic, Ph.D	University of Texas Health – San Antonio	Flow and Tissue Cytometry	University of Utah	Type A	2023
Engineering degron system in human CD34+ cells to study dosage effects of endogenous transcription factors	Charles Antony, PhD Mentor Vikram Paralkar	Perelman School of Medicine	Yale CCEH	Yale Cell Preparation and Analysis Core	Type B	2023
Transcriptional Mechanisms that Accelerate Red Blood Cell Production in Anemia	Kyle Hewitt, PhD	University of Nebraska School of Medicine	Cell Production CD34+ Core	Fred Hutchinson CCEH	Type B	2023
Intrinsic regulation of erythropoiesis by the cholesterol synthesis pathway	Christina Termini, Ph.D.	Fred Hutchinson Cancer Center	Fred Hutchinson Vector Core	Fred Hutchinson CCEH	Type B	2023
Multiplex imaging of the regenerating bone marrow microenvironment	Christina Termini, Ph.D.	Fred Hutchinson Cancer Center	CODEX Imaging Core Indiana	Indiana University Medical School	Type A	2023
Understanding the exosomal communication of bone marrow stromal cells with hematopoietic stem and progenitor cells	Reza Shahbazi, Ph.D.	Indiana University Simon Comprehensive Cancer Center	Cell preparation and Analysis	Fred Hutchinson	Type A	2023
HMGA1 in Cardiovascular Disease Associated with TET2 Mutant Clonal Hematopoiesis	Zanshé Thompson, PhD	Johns Hopkins School of Medicine	Cell preparation and Analysis	Yale University	Type A	2023
The function of ANKRD26 and its role in megakaryopoiesis	Liang Zheng, PhD	Yale University	Cell Preparation and Analysis	Yale University	Type B	2023
Lipid perturbations in the red blood cell due to hypoxia, sickle cell disease and malaria infection	Radoslaw Omelianczyk, PhD	University of Utah	Metabolomics	University of Utah	Type B	2023
Developing an AAV-based gene editing tool to model aberrant RNA splicing in hematopoiesis	Sayantani Sinha, PhD	Fred Hutchinson/University of Washington	Vector Production	Fred Hutchinson	Type A	2023
C-FiSHH — a CRISPR-based Functional in vivo Screen of Human Hematopoiesis	Emily Collins, PhD	Fred Hutchinson	Vector Production	Fred Hutchinson	Type B	2023
Surprising activity of a small molecule compound on myeloid progenitors	Shangqin Guo, PhD	Yale University	Metabolomics	University of Utah	Type A	2023
Driving myeloid progenitor expansion with small molecules	Stephen Maxwell Scalf, PhD	Yale University	Flow Cytometry, Cell Preparation and Analysis	Yale University	Type B	2022
Targeting fatty acid oxidation to expand hematopoietic stem cells	Peter S Klein, MD, PhD	University of Pennsylvania School of Medicine	Cell Procurement and Resource Development	Fred Hutchinson Cancer Center	Type B	2022
Adapting multiplexed high-resolution imaging to investigate the hematopoietic niche of bone marrow	Sonali J. Karnik, PhD	Indiana University School of Medicine	Flow and Tissue Cytometry (FTCC)	Indiana University School of Medicine	Type A	2022
Iron-Regulatory Protein 2 Phosphorylation Regulation of Erythropoiesis	Elizabeth A Leibold, PhD	University of Utah School of Medicine	Iron and Heme Core Utah CIHD	University of Utah	Type A	2022
Investigation of RBM15 and the m6A epitranscriptome in megakryopoiesis	Madeline Mayday, BS	Yale School of Medicine	N/A	Yale University	Type B	2022
TERT Splice Variants and Myelopoiesis in Diabetic CD34+ cells	Yagna Prasada Rao Jarajapu, PhD	North Dakota State University	Experimental Mouse Model	Indiana University	Type B	2022
Novel mechanisms of action of HFE in hepcidin an diron homeostasis regulation	Xia Xiao, PhD	Harvard Medical School	Bioinformatics	Cincinnati Children’s	Type B	2022
Fine-Tuning of Hemoglobinization Through Heme Import by Erythrocytic HRG1	Audrey Belot, PhD	University of Maryland	Iron and Heme	University of Utah	Type B	2022

Project Title	PI	Investigator Institution	Core Utilized	CCEH Center	Award Type	Year	hf:tax:cceh-center	hf:tax:pf-project-year
Modeling splicing factor mutations in human hematopoiesis using AAV6-based gene editing technology	Elana Thieme, BS	Fred Hutch Cancer Center	Cell Manipulations Tools Core / Vector Production	Fred Hutch	Type A	2025	fred-hutch	2025
Interplay of RNA methylation and transcription elongation during human erythropoiesis	Kaustav Mukherjee, PhD	Mount Sinai, School of Medicine	Cell Preparation and Analysis Core	Yale	Type A	2025	yale	2025
Metabolic Determinants of In Vitro Hematopoiesis	Rong Qiu, MD, PhD	Children's Hospital of Philadelphia	Metabolomics, Proteomics and Mass Spectrometry Core	Utah	Type A	2025	utah	2025
Uncovering the Spatial Architecture of Hematopoietic and Mesenchymal Niches During Fracture Healing Using CODEX Imaging	Deepak Kumar Khajuria, PhD	Indiana University	Flow & Tissue Cytometry Core	Indiana	Type A	2025	indiana	2025
Purifying the syndecan-2 bone marrow interactome	Kayleigh Robichaux, PhD	Fred Hutch Cancer Center	Cell Manipulations Tools Core / Vector Production	Fred Hutch	Type A	2025	fred-hutch	2025
Nuclear envelope protein emerin regulates structure and function of the erythrocyte membrane	Brendan J. O'Brien, PhD	Yale University	Imaging Core and Cell Preparation and Analysis Core	Yale	Type A	2025	yale	2025
Investigating metabolite-driven regulation of calreticulin	Nicole Arellano	University of Utah	Protein-Metabolite Discovery Core	Utah	Type A	2025	utah	2025
Training a machine learning model to identify long-term engrafting HSCs	Helong Gary Zhao, PhD	Fred Hutchinson Cancer Center	Hematopoietic Cell Procurement and Processing Core	Fred Hutch	Type A	2024	fred-hutch	2024
Fine-Tuning of Hemoglobinization Through Heme Import by Erythrocytic HRG1	Audrey Belot, PhD	University of Maryland	Iron and Heme Core	Utah	Type B	2022	utah	2022
Novel mechanisms of action of HFE in hepcidin and iron homeostasis regulation	Xia Xiao, PhD	Mass General Hospital/Harvard Medical School	Bioinformatics Core	Cincinnati	Type B	2022	cincinnati	2022
TERT Splice Variants and Myelopoiesis in Diabetic CD34+ cells	Yagna Prasada Rao Jarajapu, PhD	North Dakota State University	IU-CCEH Experimental mouse model core	Indiana	Type B	2022	indiana	2022
Investigation of RBM15 and the m6A epitranscriptome in megakaryopoiesis	Madeline Mayday, BS	Yale School of Medicine	None	Yale	Type B	2022	yale	2022
Iron-Regulatory Protein 2 Phosphorylation Regulation of Erythropoiesis	Elizabeth Leibold, PhD	University of Utah School of Medicine	Utah Iron and Heme Core	Utah	Type A	2022	utah	2022
Adapting multiplexed high-resolution imaging to investigate the hematopoietic niche of bone marrow	Sonali J. Karnik, PhD	Indiana University School of Medicine	Flow and Tissue Cytometry Core (FTCC) of the IU-CCEH	Indiana	Type A	2022	indiana	2022
Targeting fatty acid oxidation to expand hematopoietic stem cells	Peter S Klein, MD, PhD	University of Pennsylvania School of Medicine	Cell Procurement and Resource Development Core Fred Hutchinson CCEH		Type B	2022		2022
Driving myeloid progenitor expansion with small molecules	Stephen Maxwell Scalf, PhD	Yale School of Medicine	Flow Cytometry Core and Yale CCEH Cell Preparation and Analysis Core	Yale	Type B	2022	yale	2022
Surprising activity of a small molecule compound on myeloid progenitors	Shangqin Guo, PhD	Yale School of Medicine	Utah Metabolomics	Yale	Type A	2023	yale	2023
HMGA1 in Cardiovascular Disease Associated with TET2 Mutant Clonal Hematopoiesis	Zanshé Thompson, PhD	Johns Hopkins School of Medicine	Yale Cell preparation and Analysis		Type A	2023		2023
Understanding the exosomal communication of bone marrow stromal cells with hematopoietic stem and progenitor cells	Reza Shahbazi, PhD	Indiana University Simon Comprehensive Cancer Center	Fred Hutchinson Cell Preparation and Analysis	Indiana	Type A	2023	indiana	2023
Developing an AAV-based gene editing tool to model aberrant RNA splicing in hematopoiesis	Sayantani Shinha, PhD	Fred Hutchinson/University of Washington	Vector Production Core	Fred Hutch	Type A	2023	fred-hutch	2023
C-FiSHH – a CRISPR-based Functional in vivo Screen of Human Hematopoiesis	Emily Collins, PhD	Fred Hutchinson Cancer Center	Fred Hutchinson Vector Core	Fred Hutch	Type B	2023	fred-hutch	2023
Lipid perturbations in the red blood cell due to hypoxia, sickle cell disease and malaria infection	Radoslaw Omelianczyk, PhD	University of Utah School of Medicine	Metabolomics Core	Utah	Type B	2023	utah	2023
The function of ANKRD26 and its role in megakaryopoiesis	Liang Zheng, PhD	University of Kansas Medical Center	Yale Cell Preparation and Analysis Core	Yale	Type B	2023	yale	2023
Multiplex imaging of the regenerating bone marrow microenvironment	Christina Termini, PhD	Fred Hutchinson Cancer Center	CODEX Imaging Core Indiana	Fred Hutch	Type A	2023	fred-hutch	2023
Using a Novel CODEX Antibody Panel for Spatial Cellular Proteomics of the Bone Hematopoietic and Vascular Niches under Systemic Thrombopoietin Treatment	Patrick L. Mulcrone, PhD	Indiana University School of Medicine	Flow and Tissue Cytometry Core CODEX Indiana University	Indiana	Type A	2023	indiana	2023
Interactions between heme export and choline import via FLVCR1	Janis Abkowitz, MD	University of Washington	Metabolomics Core Utah CCEH, Iron and Heme Core Utah CCEH	Utah	Type A	2023	utah	2023
Investigating aging-related changes in the bone marrow matrix and hematopoietic stem cell niche using multiplexed spatial-resolution imaging	Milos Marinkovic, PhD	University of Texas Health – San Antonio	Flow and Tissue Cytometry Core CODEX Indiana University		Type A	2023		2023
Intrinsic regulation of erythropoiesis by the cholesterol synthesis pathway	Christina Termini, PhD	Fred Hutchinson Cancer Center	Fred Hutchinson Vector Core	Fred Hutch	Type B	2023	fred-hutch	2023
Transcriptional Mechanisms that Accelerate Red Blood Cell Production in Anemia	Kyle Hewitt, PhD	University of Nebraska School of Medicine	Fred Hutchinson CCEH Cell Production CD34+ Core		Type B	2023		2023
Metabolic Changes in Erythroblasts from Iron-Regulatory Protein 2 Phosphorylation Mutant Mice	Elizabeth A. Leibold, PhD	University of Utah School of Medicine	Utah Metabolomics Core		Type A	2024		2024
Metabolic determinants of MEP fate specification	Rubia Isler Mancuso, PhD	Yale	Utah Metabolomics Core	Yale	Type A	2024	yale	2024
Improving hematopoietic stem cell quantification in a sickle cell disease context	Kim Vanuytsel, PhD	Boston Medical Center	Yale CCEH Primary Cells CD34+ Core		Type B	2024		2024
Investigation of selective autophagy receptor optineurin in erythropoiesis	Massiel Chavez Stolla, PhD	University of Washington School of Medicine		Fred Hutch	Type B	2024	fred-hutch	2024
Gene Expression Profiling to Predict Hematopoietic Cell Potency in Transplantation	James Ropa, PhD	Indiana University School of Medicine	IU-CCEH Flow Cytometry and Cincinnati Children’s CCEH DNA Sequencing Cores	Indiana	Type B	2024	indiana	2024
The function of neutrophilic granule protein in hematopoietic development	Kostadin Pajcini, PhD	University of Illinois at Chicago	Cincinnati Transgenic Animal and Genome Editing Core		Type A	2024		2024
Critical Role of a SNP in the SENP1 gene regulation and excessive erythrocytosis at high altitude	Priti Azad, Ph.D.	University of San Diego	Yale Cell Procurement Core	Yale	Type A	2024	yale	2024
Investigating Long-Term Genome Editing Safety in Hematopoietic Stem Cells	Phillip A Doerfler, PhD	Versiti Blood Research Institute	Fred Hutchinson Cell Procurement Core		Type A	2024		2024
Minimal manipulation of HPSCs and novel viral vectors for faster, efficient transduction of hematopoietic stem and progenitor cells	Rachel Bakyayita Kyeyune, MBChB, PhD	Fred Hutchinson Cancer Center	Fred Hutchinson Cell Procurement and Processing	Fred Hutch	Type A	2024	fred-hutch	2024
Changes in the bone marrow microenvironment in cystic fibrosis	Emanuela Bruscia, PhD	Yale University School of Medicine	Indiana CODEX Imaging Core	Indiana	Type A	2024	indiana	2024
Dissecting microenvironmental metabolic contributions to erythropoiesis	Marlies P Rossman, PhD	University of Rochester	Cincinnati CCEH Single Cell Characterization and Procurement Core		Type B	2024		2024
UPLC Analysis of Porphyrin Biochemistry in a Planarian Model of Acute Porphyrias	Jason Pellettieri, PhD	Boston Children’s Hospital	Iron and Heme Core Utah	Utah	Type A	2022	utah	2022
Engineering degron system in human CD34+ cells to study dosage effects of endogenous transcription factors	Charles Antony, PhD	Perelman School of Medicine	Yale Cell Preparation and Analysis Core		Type B	2023		2023
Uncovering RNA isoform diversity and functionality in hematopoietic cell-fate determination	Stanley Lee, PhD	Fred Hutchinson Cancer Center	None	Fred Hutch	Type B	2024	fred-hutch	2024
Regulation of hematopoietic stem cell quiescence by a proteoglycan protein	YoonA Kang, PhD	Washington University School of Medicine	Fred Hutchinson CCEH Cell Procurement and Processing Core		Type B	2024		2024

Meet the Investigators

Get to know the investigators behind our current P&F projects. Click on an investigator’s name to visit their website.

Diane Krause, MD, PhD Marlies P Rossman, PhD Stanley Lee, PhD YoonA Kang, PhD Gary Zhao, PhD Liang Zheng, PhD Radoslaw Omelianczyk, PhD Sayantani Sinha, PhD Emily Collins, PhD Madeline Mayday, BS Yagna Prasada Rao Jarajapu, PhD Xia Xiao, PhD Audrey Belot, PhD Sonali J. Karnik, PhD Elizabeth A Leibold, PhD Stephen Maxwell Scalf, PhD Peter S Klein, MD, PhD Shangqin Guo, PhD Zanshé Thompson, PhD Reza Shahbazi Charles Antony, PhD Patrick Mulcrone, PhD Kyle Hewitt, PhD Christina Termini, PhD Janis L Abkowitz, MD Milos Marinkovic, Ph.D James Ropa, PhD Massiel Chavez Stolla, PhD Kim Vanuytsel, PhD Dr. Priti Azad